HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dan H Barouch Selected Research

vesatolimod

5/2022Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques.
1/2022HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys.
11/2018Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Dan H Barouch Research Topics

Disease

88Infections
02/2022 - 01/2002
51COVID-19
10/2022 - 01/2020
10Viremia
01/2022 - 03/2003
10Neoplasms (Cancer)
10/2021 - 09/2013
9Vaccinia
05/2022 - 03/2009
9Inflammation (Inflammations)
01/2022 - 04/2014
8Acquired Immunodeficiency Syndrome (AIDS)
12/2018 - 01/2002
7HIV Infections (HIV Infection)
01/2022 - 01/2016
7Zika Virus Infection
01/2021 - 10/2016
6Weight Loss (Weight Reduction)
01/2022 - 01/2020
5Virus Diseases (Viral Diseases)
11/2020 - 06/2002
4Pain (Aches)
10/2021 - 01/2020
4Melanoma (Melanoma, Malignant)
01/2021 - 01/2017
4Communicable Diseases (Infectious Diseases)
01/2021 - 07/2005
3Thrombosis (Thrombus)
05/2022 - 11/2020
3Persistent Infection
01/2022 - 08/2015
3Headache (Headaches)
10/2021 - 01/2020
3Fatigue
01/2021 - 01/2020
3Disease Progression
01/2021 - 01/2002
2Breakthrough Infections
01/2022 - 09/2012
2Asymptomatic Infections
09/2021 - 01/2021
2Pneumonia (Pneumonitis)
03/2021 - 11/2020
2Myalgia
01/2021 - 01/2020
2Dengue (Dengue Fever)
01/2021 - 01/2020
2Smallpox (Variola)
03/2009 - 07/2008
1Reinfection
01/2022
1Severe Acute Respiratory Syndrome
01/2022
1Bites and Stings (Sting)
05/2021
1Respiratory Tract Infections (Respiratory Tract Infection)
03/2021
1Common Cold
03/2021
1Fever (Fevers)
01/2021

Drug/Important Bio-Agent (IBA)

100VaccinesIBA
05/2022 - 01/2002
23AntibodiesIBA
03/2022 - 10/2013
18Neutralizing AntibodiesIBA
03/2022 - 03/2003
15Proteins (Proteins, Gene)FDA Link
05/2022 - 10/2016
13Broadly Neutralizing AntibodiesIBA
01/2022 - 03/2016
13AntigensIBA
03/2021 - 07/2005
11Ad26COVS1IBA
01/2022 - 01/2021
10Immunoglobulin G (IgG)IBA
01/2022 - 02/2015
8Monoclonal AntibodiesIBA
10/2022 - 10/2003
8DNA (Deoxyribonucleic Acid)IBA
03/2021 - 03/2003
7Antiviral Agents (Antivirals)IBA
01/2022 - 08/2015
5casirivimab and imdevimab drug combinationIBA
10/2022 - 01/2021
5EpitopesIBA
01/2021 - 01/2002
4CytokinesIBA
01/2016 - 01/2002
3COVID-19 VaccinesIBA
10/2022 - 11/2020
3vesatolimodIBA
05/2022 - 11/2018
3mRNA VaccinesIBA
01/2022 - 01/2021
3Messenger RNA (mRNA)IBA
01/2022 - 11/2020
3Complement System Proteins (Complement)IBA
01/2022 - 02/2015
3SARS-CoV-2 spike proteinIBA
03/2021 - 10/2020
3Peptides (Polypeptides)IBA
01/2021 - 01/2017
3Biological ProductsIBA
12/2020 - 09/2014
2GP 140IBA
05/2022 - 01/2018
2Biomarkers (Surrogate Marker)IBA
01/2022 - 01/2021
2Interferon Type IIBA
01/2022 - 10/2017
2AKB-9778IBA
10/2021 - 05/2021
2Interleukin-6 (Interleukin 6)IBA
10/2021 - 11/2020
2Angiopoietin-2IBA
10/2021 - 05/2021
2Viral AntigensIBA
01/2021 - 01/2021
2Serine Proteases (Serine Protease)IBA
12/2020 - 02/2008
2Glycoproteins (Glycoprotein)IBA
07/2020 - 09/2019
2Polysaccharides (Glycans)IBA
11/2018 - 02/2015
2Adenovirus VaccinesIBA
01/2018 - 08/2011
2Viral RNAIBA
01/2016 - 01/2002
2RNA (Ribonucleic Acid)IBA
06/2010 - 05/2010
2DNA VaccinesIBA
05/2010 - 07/2005
2AIDS VaccinesIBA
01/2002 - 01/2002
1aluminum sulfate (alum)IBA
05/2022
1Activins (Activin)IBA
05/2022
1Indicators and Reagents (Reagents)IBA
05/2022
1ADAMTS13 ProteinIBA
05/2022
1ADM03820IBA
03/2022
1N-methyl-valyl-amiclenomycin (BA 2)IBA
02/2022
1Nucleocapsid ProteinsIBA
01/2022
1GS-CA1IBA
01/2022
1Immune Sera (Antisera)IBA
01/2022
1Formaldehyde (Formol)FDA Link
01/2022
1InterferonsIBA
01/2022
1bictegravirIBA
11/2021
1emtricitabine tenofovir alafenamideIBA
11/2021
1AngiopoietinsIBA
10/2021
1Immune Checkpoint InhibitorsIBA
10/2021
1Pattern Recognition ReceptorsIBA
05/2021
1EmulsionsIBA
05/2021
1Aluminum Hydroxide (Algeldrate)FDA Link
05/2021
1AnticoagulantsIBA
05/2021
1von Willebrand FactorIBA
05/2021
1Explosive Agents (Explosives)IBA
03/2021
1Subgenomic RNAIBA
01/2021
1T-Cell Antigen Receptors (T-Cell Receptor)IBA
01/2021
1Viral DNAIBA
01/2021
1Adenosine Monophosphate (AMP)IBA
01/2021
1HLA Antigens (Human Leukocyte Antigens)IBA
01/2021
1Protein Subunit VaccinesIBA
01/2021

Therapy/Procedure

16Therapeutics
03/2022 - 05/2010
3Art Therapy
01/2019 - 08/2014
2Aftercare (After-Treatment)
01/2021 - 01/2020
1Intravenous Injections
10/2021
1Subcutaneous Injections
01/2021